Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 217131
Company: FRESENIUS KABI USA
Company: FRESENIUS KABI USA
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| ASCORBIC ACID | ASCORBIC ACID | 25,000MG/50ML (500MG/ML) | SOLUTION;INTRAVENOUS | Prescription | AP | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 08/07/2025 | ORIG-1 | Approval | STANDARD |
Label is not available on this site. |
ASCORBIC ACID
SOLUTION;INTRAVENOUS; 25,000MG/50ML (500MG/ML)
TE Code = AP
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| ASCOR | ASCORBIC ACID | 25,000MG/50ML (500MG/ML) | SOLUTION;INTRAVENOUS | Prescription | Yes | AP | 209112 | MCGUFF |
| ASCORBIC ACID | ASCORBIC ACID | 25,000MG/50ML (500MG/ML) | SOLUTION;INTRAVENOUS | Prescription | No | AP | 217131 | FRESENIUS KABI USA |